Add Basal Insulin and Discontinue Gliclazide
In a patient with type 2 diabetes inadequately controlled on metformin 850 mg BID plus gliclazide MR 60 mg daily, you should initiate basal insulin while continuing metformin and stopping the sulfonylurea (gliclazide). This approach is strongly supported by the most recent ADA/EASD consensus guidelines 1, 2.
Rationale for This Recommendation
The 2026 ADA/EASD consensus explicitly states that when initiating insulin therapy, "medications that promote hypoglycemia and weight gain (such as sulfonylureas) should be stopped, while agents that promote weight loss, reduce insulin needs, and limit hypoglycemia (such as metformin, SGLT2 inhibitors, or GLP-1-based therapy) should be maintained" 1. The 2024 ADA Standards of Care reinforces this, recommending to "reassess the need for and/or dose of glucose-lowering agents with higher hypoglycemia risk (i.e., sulfonylureas and meglitinides)" when starting insulin 2.
Practical Implementation
Starting basal insulin:
- Begin with basal insulin analog (glargine, detemir, or once-weekly insulin) at 0.1-0.3 units/kg/day 3
- Titrate based on fasting glucose levels
- Continue metformin throughout (maintains insulin sensitivity, reduces insulin requirements, limits weight gain) 1, 4
Why stop gliclazide:
- Sulfonylureas combined with insulin significantly increase hypoglycemia risk 4
- They promote weight gain, which is already a concern with insulin therapy 1
- Metformin alone provides sufficient oral agent support when combined with basal insulin 5
Evidence Supporting This Approach
Analysis of 2,171 patients adding insulin glargine showed that those on metformin monotherapy at baseline achieved better glycemic control (68.1% reaching HbA1c ≤7.0%) compared to those on metformin plus sulfonylurea combination (56.4%, p=0.0006) 5. Critically, patients on metformin alone experienced significantly less hypoglycemia despite requiring higher insulin doses 5.
Alternative Consideration (Less Preferred)
Before defaulting to insulin, consider whether the patient has comorbidities that would prioritize GLP-1 receptor agonists instead. The 2024 ADA guidelines state that "a GLP-1 RA, including a dual GIP and GLP-1 RA, is preferred to insulin" 2. However, if insulin is clinically indicated (severe hyperglycemia, symptoms, weight loss, or cost constraints), proceed with the basal insulin plus metformin regimen as outlined above.
Critical Pitfalls to Avoid
- Do not continue sulfonylurea with insulin - this doubles the hypoglycemia risk without meaningful glycemic benefit 1, 2, 4
- Do not simply increase gliclazide dose - the patient has already failed dual oral therapy at substantial doses; further sulfonylurea escalation increases hypoglycemia risk without addressing the underlying beta-cell dysfunction 1
- Monitor closely after insulin initiation - reassess within 2-4 weeks and titrate insulin dose based on fasting glucose 1
- Ensure patient has diabetes self-management education when starting insulin 1